Molecure (WAR:MOC) Ending Cash Position: zł22.46 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:MOC Molecure SA WAR:MOC
27 GF Score
Price zł6.19
! 3 Warning Signs
View Full Analysis

What is Molecure Ending Cash Position?

Molecure WAR:MOC +0.65% 27 Ending Cash Position is zł22.46 Mil as of Sep. 2025. GuruFocus rates WAR:MOC with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

Molecure's Ending Cash Position for the quarter that ended in Sep. 2025 was zł22.46 Mil.

Molecure's quarterly Ending Cash Position declined from Mar. 2025 (zł40.66 Mil) to Jun. 2025 (zł32.40 Mil) and declined from Jun. 2025 (zł32.40 Mil) to Sep. 2025 (zł22.46 Mil).

Molecure's annual Ending Cash Position declined from Dec. 2022 (zł65.62 Mil) to Dec. 2023 (zł63.99 Mil) and declined from Dec. 2023 (zł63.99 Mil) to Dec. 2024 (zł18.19 Mil).

Molecure Ending Cash Position Related Terms

Molecure Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Molecure's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecure Ending Cash Position Chart

Molecure Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 120.50 102.04 65.62 63.99 18.19

Molecure Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.58 18.19 40.66 32.40 22.46
WAR:MOC
27GF Score
Molecure SA WAR:MOC
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecure Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Molecure's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=63.988+-45.8
=18.19

Molecure's Ending Cash Position for the quarter that ended in Sep. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=32.688+-10.227
=22.46

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of zł22.46 Mil mean?
Molecure (WAR:MOC) has a Ending Cash Position of zł22.46 Mil as of Sep. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Molecure and its competitors.
Is Molecure's Ending Cash Position too high?
Molecure's current Ending Cash Position is zł22.46 Mil. Overall, Molecure has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Molecure's Ending Cash Position compare to VRTX and REGN?
Molecure's Ending Cash Position of zł22.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Molecure and its competitors. Molecure's current Ending Cash Position is zł22.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecure stock overvalued right now?
Molecure (WAR:MOC) has a current Ending Cash Position of zł22.46 Mil. The current Ending Cash Position is zł22.46 Mil. Molecure's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Molecure (WAR:MOC), the current Ending Cash Position is zł22.46 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Molecure Business Description

Other Exchanges 1B1:Germany
Address Zwirki i Wigury 101, Warsaw, POL, 02-089
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.
27GF Score

Get the complete analysis for WAR:MOC

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł6.19
Price